What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
The treatment of invasive candidiasis has changed greatly in the past decade and must continue to evolve if we are to improve outcomes in this serious infection. A review of recent history may provide insights for the future. The morbidity and mortality of invasive candidiasis remain difficult to measure despite an obvious clinical burden. Current treatment guidelines now recommend echinocandins as first-line empirical treatment, with fluconazole as an acceptable alternative for selected patients, reflecting the efficacy demonstrated by echinocandins and increasing resistance observed with fluconazole. The selection of antifungal therapy now must consider not only resistance but also the shift in predominance from Candida albicans to non-albicans species, notably Candida glabrata. The recent emergence of Candida auris has been met with great interest, although the longer-term implications of this phenomenon remain unclear. The broad goal of treatment continues to be administration of safe, efficacious antifungal therapy as soon as possible. Diagnostic methods beyond traditional blood culture present an opportunity to shorten the time to an accurate diagnosis, and earlier treatment initiation based on prophylactic and empirical or pre-emptive strategies seeks to ensure timely therapeutic intervention. In addition, there are novel agents in the antifungal pipeline. These developments, as well as ongoing studies of dosing, toxicity and resistance development, are important items on the current research agenda and may play a role in future changes to the treatment of invasive candidiasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Kullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315
Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217
Self-citationGarey, K. W., Rege, M., Pai, M. P., Mingo, D. E., Suda, K. J., Turpin, R. S., & Bearden, D. T. (2006) · Clinical Infectious Diseases · doi:10.1086/504810 · Cited by 1,171
Attributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131
Research works printed but not linked: 86
- Goldstein, 1972, Problems in the diagnosis and treatment of systemic candidiasis, J Infect Dis, 125, 190, 10.1093/infdis/125.2.190 · DOI · Paper page
- Appleyard, 1969, Candida septicaemia, Br Med J, 1, 577, 10.1136/bmj.1.5643.577 · doi:10.1136/bmj.1.5643.577
- Shurtleff, 1963, Systemic candida tropicalis infection treated with amphotericin, N Engl J Med, 269, 1112, 10.1056/NEJM196311212692102 · DOI
- Cornely, 2015, Hepatosplenic candidiasis, Clin Liver Dis, 6, 10.1002/cld.491 · DOI
- Koehler, 2016, Contemporary strategies in the prevention and management of fungal infections, Infect Dis Clin North Am, 30, 265, 10.1016/j.idc.2015.10.003 · DOI
- Knitsch, 2015, A randomized, placebo-controlled trial of preemptive antifungal therapy for the prevention of invasive candidiasis following gastrointestinal surgery for intra-abdominal infections, Clin Infect Dis, 61, 1671, 10.1093/cid/civ707 · DOI · Paper page
- Eliakim-Raz, 2016, Epidemiology, microbiology, clinical characteristics, and outcomes of candidemia in internal medicine wards-a retrospective study, Int J Infect Dis, 52, 49, 10.1016/j.ijid.2016.09.018 · DOI
- Bassetti, 2006, Epidemiological trends in nosocomial candidemia in intensive care, BMC Infect Dis, 6, 21., 10.1186/1471-2334-6-21 · DOI · Paper page
- Cornely, 2015, Epidemiology and outcome of fungemia in a cancer cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031), Clin Infect Dis, 61, 324, 10.1093/cid/civ293 · DOI · Paper page
- Pappas, 2016, Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America, Clin Infect Dis, 62, e1, 10.1093/cid/civ1194 · DOI · Paper page
- Bassetti, 2017, Intensive care medicine research agenda on invasive fungal infection in critically ill patients, Intensive Care Med, 10.1007/s00134-017-4731-2 · DOI · Paper page
- Rex, 2003, A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects, Clin Infect Dis, 36, 1221, 10.1086/374850 · DOI · Paper page
- Pappas, 2007, Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis, Clin Infect Dis, 45, 883, 10.1086/520980 · DOI · Paper page
- Blot, 2002, Effects of nosocomial candidemia on outcomes of critically ill patients, Am J Med, 113, 480, 10.1016/S0002-9343(02)01248-2 · DOI · Paper page
- Lortholary, 2017, The risk and clinical outcome of candidemia depending on underlying malignancy, Intensive Care Med, 43, 652, 10.1007/s00134-017-4743-y · DOI · Paper page
- Koehler, 2014, Our 2014 approach to candidaemia, Mycoses, 57, 581, 10.1111/myc.12207 · DOI
- Mann, 2009, Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species, Antimicrob Agents Chemother, 53, 5026, 10.1128/AAC.01031-09 · DOI · Paper page
- Seifert, 2007, In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates, Antimicrob Agents Chemother, 51, 1818, 10.1128/AAC.01217-06 · DOI · Paper page
- Metwally, 2007, Trends in candidemia and antifungal susceptibility in a university hospital in Northern Ireland 2001-2006, J Infect, 55, 174, 10.1016/j.jinf.2007.04.003 · DOI
- Sharma, 2015, Draft genome sequence of a fluconazole-resistant Candida auris strain from a candidemia patient in India, Genome Announc, 3, 10.1128/genomeA.00722-15 · DOI · Paper page
- Ruiz Gaitan, 2017, Nosocomial fungemia by Candida auris: first four reported cases in continental Europe, Rev Iberoam Micol, 34, 23, 10.1016/j.riam.2016.11.002 · DOI · Paper page
- Tsay, 2017, Notes from the field: ongoing transmission of Candida auris in health care facilities—United States, June 2016-May 2017, MMWR Morb Mortal Wkly Rep, 66, 514, 10.15585/mmwr.mm6619a7 · DOI · Paper page
- Clancy, 2017, Emergence of Candida auris: an international call to arms, Clin Infect Dis, 64, 141, 10.1093/cid/ciw696 · DOI · Paper page
- Leon, 2012, Value of β-d-glucan and Candida albicans germ tube antibody for discriminating between Candida colonization and invasive candidiasis in patients with severe abdominal conditions, Intensive Care Med, 38, 1315, 10.1007/s00134-012-2616-y · DOI
- Held, 2013, Comparison of (1->3)-β-d-glucan, mannan/anti-mannan antibodies, and Cand-Tec Candida antigen as serum biomarkers for candidemia, J Clin Microbiol, 51, 1158, 10.1128/JCM.02473-12 · DOI · Paper page
- Martinez-Jimenez, 2015, Combination of Candida biomarkers in patients receiving empirical antifungal therapy in a Spanish tertiary hospital: a potential role in reducing the duration of treatment, J Antimicrob Chemother, 70, 3107, 10.1093/jac/dkv241 · DOI · Paper page
- Bille, 2010, New nonculture-based methods for the diagnosis of invasive candidiasis, Curr Opin Crit Care, 16, 460, 10.1097/MCC.0b013e32833e04df · DOI
- Avni, 2011, PCR diagnosis of invasive candidiasis: systematic review and meta-analysis, J Clin Microbiol, 49, 665, 10.1128/JCM.01602-10 · DOI · Paper page
- Wallet, 2010, Preliminary clinical study using a multiplex real-time PCR test for the detection of bacterial and fungal DNA directly in blood, Clin Microbiol Infect, 16, 774, 10.1111/j.1469-0691.2009.02940.x · DOI
- van Deventer, 1996, Kinetics of anti-mannan antibodies useful in confirming invasive candidiasis in immunocompromised patients, Microbiol Immunol, 40, 125, 10.1111/j.1348-0421.1996.tb03327.x · DOI
- Caggiano, 2011, Candida colonization index in patients admitted to an ICU, Int J Mol Sci, 12, 7038, 10.3390/ijms12107038 · DOI
- Bassetti, 2013, A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts, Intensive Care Med, 39, 2092, 10.1007/s00134-013-3109-3 · DOI · Paper page
- Leon, 2014, What's new in the clinical and diagnostic management of invasive candidiasis in critically ill patients, Intensive Care Med, 40, 808, 10.1007/s00134-014-3281-0 · DOI
- Liss, 2016, 1,3-β-d-Glucan contamination of common antimicrobials, J Antimicrob Chemother, 71, 913, 10.1093/jac/dkv419 · DOI · Paper page
- Liss, 2016, 1,3-ss-d-Glucan concentrations in blood products predict false positive post-transfusion results, Mycoses, 59, 39, 10.1111/myc.12432 · DOI · Paper page
- Mikulska, 2016, Lower sensitivity of serum (1,3)-β-d-glucan for the diagnosis of candidaemia due to Candida parapsilosis, Clin Microbiol Infect, 22, 646.e5, 10.1016/j.cmi.2016.05.020 · DOI
- Tissot, 2013, β-Glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis, Am J Respir Crit Care Med, 188, 1100, 10.1164/rccm.201211-2069OC · DOI · Paper page
- Martin-Mazuelos, 2015, β-d-Glucan and Candida albicans germ tube antibody in ICU patients with invasive candidiasis, Intensive Care Med, 41, 1424, 10.1007/s00134-015-3922-y · DOI
- Hanson, 2012, β-d-Glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study, PLoS One, 7, e42282, 10.1371/journal.pone.0042282 · DOI · Paper page
- Posteraro, 2011, Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1–>3)-β-d-glucan assay, Candida score, and colonization index, Crit Care, 15, R249, 10.1186/cc10507 · DOI · Paper page
- Jaijakul, 2012, 1,3)-β-d-Glucan as a prognostic marker of treatment response in invasive candidiasis, Clin Infect Dis, 55, 521, 10.1093/cid/cis456 · DOI · Paper page
- Koo, 2012, Post-diagnostic kinetics of the (1 –> 3)-β-d-glucan assay in invasive aspergillosis, invasive candidiasis and Pneumocystis jirovecii pneumonia, Clin Microbiol Infect, 18, E122, 10.1111/j.1469-0691.2012.03777.x · DOI · Paper page
- Poissy, 2014, Presence of Candida cell wall derived polysaccharides in the sera of intensive care unit patients: relation with candidaemia and Candida colonisation, Crit Care, 18, R135., 10.1186/cc13953 · DOI
- Peman, 2011, Clinical factors associated with a Candida albicans germ tube antibody positive test in intensive care unit patients, BMC Infect Dis, 11, 60, 10.1186/1471-2334-11-60 · DOI
- Martinez-Jimenez, 2014, Potential role of Candida albicans germ tube antibody in the diagnosis of deep-seated candidemia, Med Mycol, 52, 270, 10.1093/mmy/myt025 · DOI
- Mylonakis, 2015, T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial, Clin Infect Dis, 60, 892, 10.1093/cid/ciu959 · DOI · Paper page
- Gorton, 2014, Comparative analysis of Gram's stain, PNA-FISH and Sepsityper with MALDI-TOF MS for the identification of yeast direct from positive blood cultures, Mycoses, 57, 592, 10.1111/myc.12205 · DOI
- Wattal, 2017, Matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) for rapid identification of micro-organisms in the routine clinical microbiology laboratory, Eur J Clin Microbiol Infect Dis, 36, 807, 10.1007/s10096-016-2864-9 · DOI
- Huang, 2013, Impact of rapid organism identification via matrix-assisted laser desorption/ionization time-of-flight combined with antimicrobial stewardship team intervention in adult patients with bacteremia and candidemia, Clin Infect Dis, 57, 1237, 10.1093/cid/cit498 · DOI · Paper page
- Scudeller, 2014, An Italian consensus for invasive candidiasis management (ITALIC), Infection, 42, 263, 10.1007/s15010-013-0558-0 · DOI
- Azoulay, 2012, Systemic antifungal therapy in critically ill patients without invasive fungal infection, Crit Care Med, 40, 813, 10.1097/CCM.0b013e318236f297 · DOI · Paper page
- Wissing, 2013, Intensive care unit-related fluconazole use in Spain and Germany: patient characteristics and outcomes of a prospective multicenter longitudinal observational study, Infect Drug Resist, 6, 15
- Epstein, 2018, Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies, J Antimicrob Chemother, 73, i60, 10.1093/jac/dkx450 · DOI
- Giannella, 2018, Use of echinocandin prophylaxis in solid organ transplantation, J Antimicrob Chemother, 73, i51, 10.1093/jac/dkx449 · DOI
- Presterl, 2009, Invasive fungal infections and (1,3)-β-d-glucan serum concentrations in long-term intensive care patients, Int J Infect Dis, 13, 707, 10.1016/j.ijid.2008.10.013 · DOI · Paper page
- Mohr, 2011, Prospective survey of (1–>3)-β-d-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting, J Clin Microbiol, 49, 58, 10.1128/JCM.01240-10 · DOI · Paper page
- Bow, 2010, Canadian clinical practice guidelines for invasive candidiasis in adults, Can J Infect Dis Med Microbiol, 21, e122, 10.1155/2010/357076 · DOI · Paper page
- Ostrosky-Zeichner, 2014, MSG-01: a randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting, Clin Infect Dis, 58, 1219, 10.1093/cid/ciu074 · DOI · Paper page
- Leroy, 2016, Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study, Ann Intensive Care, 6, 2, 10.1186/s13613-015-0103-7 · DOI · Paper page
- Bailly, 2015, Failure of empirical systemic antifungal therapy in mechanically ventilated critically ill patients, Am J Respir Crit Care Med, 191, 1139, 10.1164/rccm.201409-1701OC · DOI
- Micek, 2014, Effects of empiric antifungal therapy for septic shock on time to appropriate therapy for Candida infection: a pilot study, Clin Ther, 36, 1226, 10.1016/j.clinthera.2014.06.028 · DOI
- Hsu, 2010, A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients, J Antimicrob Chemother, 65, 1765, 10.1093/jac/dkq216 · DOI
- Puig-Asensio, 2014, Impact of therapeutic strategies on the prognosis of candidemia in the ICU, Crit Care Med, 42, 1423, 10.1097/CCM.0000000000000221 · DOI · Paper page
- Montravers, 2016, Antifungal therapy for patients with proven or suspected Candida peritonitis: Amarcand2, a prospective cohort study in French intensive care units, Clin Microbiol Infect, 23, 117 e1, 10.1016/j.cmi.2016.10.001 · DOI
- Falagas, 2006, Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies, Crit Care, 10, R48, 10.1186/cc4869 · DOI · Paper page
- Reboli, 2011, Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome, BMC Infect Dis, 11, 261, 10.1186/1471-2334-11-261 · DOI · Paper page
- Murri, 2016, Initial antifungal strategy does not correlate with mortality in patients with candidemia, Eur J Clin Microbiol Infect Dis, 35, 187, 10.1007/s10096-015-2527-2 · DOI
- Ruhnke, 2012, Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients, Clin Microbiol Infect, 18, 680, 10.1111/j.1469-0691.2012.03784.x · DOI · Paper page
- Kett, 2011, Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis, Crit Care, 15, R253, 10.1186/cc10514 · DOI · Paper page
- Sinnollareddy, 2015, Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients study, Crit Care, 19, 33, 10.1186/s13054-015-0758-3 · DOI · Paper page
- Pea, 2018, Overview of antifungal dosing in invasive candidiasis, J Antimicrob Chemother, 73, i33, 10.1093/jac/dkx447 · DOI · Paper page
- Eschenauer, 2013, Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study, J Antimicrob Chemother, 68, 922, 10.1093/jac/dks482 · DOI · Paper page
- Lopez-Cortes, 2016, Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score-derived analysis of a population-based, multicentre prospective cohort, Clin Microbiol Infect, 22, 733.e1, 10.1016/j.cmi.2016.05.008 · DOI
- Puig-Asensio, 2016, Propensity score analysis of the role of initial antifungal therapy in the outcome of Candida glabrata bloodstream infections, Antimicrob Agents Chemother, 60, 3291, 10.1128/AAC.00195-16 · DOI
- Bassetti, 2014, A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality, Intensive Care Med, 40, 839, 10.1007/s00134-014-3310-z · DOI · Paper page
- Bailly, 2015, Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data, Intensive Care Med, 41, 1931, 10.1007/s00134-015-4053-1 · DOI
- Seyedmousavi, 2017, Systemic antifungal agents: current status and projected future developments, Methods Mol Biol, 1508, 107, 10.1007/978-1-4939-6515-1_5 · DOI
- Katragkou, 2015, Role of echinocandins in fungal biofilm-related disease: vascular catheter-related infections, immunomodulation, and mucosal surfaces, Clin Infect Dis, 61, S622, 10.1093/cid/civ746 · DOI
- Ong, 2016, Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin, Antimicrob Agents Chemother, 60, 6872, 10.1128/AAC.00701-16 · DOI · Paper page
- Pfaller, 2016, Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates, J Antimicrob Chemother, 71, 2868, 10.1093/jac/dkw214 · DOI · Paper page
- Beyda, 2014, FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia, Clin Infect Dis, 59, 819, 10.1093/cid/ciu407 · DOI · Paper page
- Ong, 2017, Pharmacokinetics of the novel echinocandin CD101 in multiple animal species, Antimicrob Agents Chemother, 61, 10.1128/AAC.01626-16 · DOI · Paper page
- Lepak, 2015, Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model, Antimicrob Agents Chemother, 59, 1265, 10.1128/AAC.04445-14 · DOI · Paper page
- Wring, 2017, Preclinical pharmacokinetics and pharmacodynamic target of SCY-078, a first-in-class orally active antifungal glucan synthesis inhibitor, in murine models of disseminated candidiasis, Antimicrob Agents Chemother, 61, 10.1128/AAC.02068-16 · DOI · Paper page
- Arvanitis, 2014, Molecular and nonmolecular diagnostic methods for invasive fungal infections, Clin Microbiol Rev, 27, 490, 10.1128/CMR.00091-13 · DOI · Paper page
- Chang, 2017, New developments and directions in the clinical application of the echinocandins, Arch Toxicol, 91, 1613, 10.1007/s00204-016-1916-3 · DOI
Cited by
Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825
Bloodstream infections in critically ill patients: an expert statement
Timsit, J.-F., Ruppé, E., Barbier, F., Tabah, A., & Bassetti, M. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05950-6 · Cited by 448
Self-citationPfaller, M. A., Carvalhaes, C., Messer, S. A., Rhomberg, P. R., & Castanheira, M. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00099-20 · Cited by 68
“posaconazole, are all employed empirically as directed therapy and for prophylaxis in patients with 60 suspected or documented invasive fungal infection (1-7).”
BackgroundAdvances in the Diagnosis and Management of Invasive Fungal Disease
Formanek, P. E., & Dilling, D. F. (2019) · Chest · doi:10.1016/j.chest.2019.06.032 · Cited by 31
Xie, J., Zhu, L., Wu, T., & Li, G. (2026) · Infection and Drug Resistance · doi:10.2147/idr.s609224
Metadata
- Authors
- Bassetti, M., Righi, E., Montravers, P., & Cornely, O. A.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-01-01
- Volume
- 73
- Issue
- suppl_1
- Pages
- i14-i25
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2781712060
- Cited by
- 98
- References
- 44
- FWCI
- 8.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- Funders
- NIH (UM1AI104681)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead. https://app.cochat.ai/papers/10.1093/jac/dkx445
- The paper
- Bassetti, M., Righi, E., Montravers, P., & Cornely, O. A. (2018). What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkx445
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.